Highest Quality Supplements Since 1980

Health Protocols

Hepatitis C


Abu-Mouch S, Fireman Z, Jarchovsky J, et al. "Vitamin D Supplementation Improves Sustained Virologic Response in Chronic Hepatitis C (Genotype 1)-Naïve Patients." World J Gastroenterol 17.47 (2011): 5184-90. http://www.ncbi.nlm.nih.gov/pubmed/22215943

Actor JK, Hwang SA, Kruzel ML. "Lactoferrin as a Natural Immune Modulator." Curr Pharm Des 17 (2009): 1956-73. http://www.ncbi.nlm.nih.gov/pubmed/19519436

Aggarwal BB, Kumar A, Bharti AC. "Anticancer Potential of Curcumin: Preclinical and Clinical Studies." Anticancer Res 23.1A (2003): 363-98. http://www.ncbi.nlm.nih.gov/pubmed/12680238

Aggarwal BB, Sundaram C, Malani N, et al. "Curcumin: the Indian Solid Gold." AdvExp Med Biol 595 (2007): 1-75. http://www.ncbi.nlm.nih.gov/pubmed/17569205

Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. "Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase." Gastroenterology 138.3 (2010): 1112-22. http://www.ncbi.nlm.nih.gov/pubmed/19962982

Alexander J, Tung BY, Croghan A, et al. "Effect of Iron Depletion on Serum Markers of Fibrogenesis, Oxidative Stress and Serum Liver Enzymes in Chronic Hepatitis C: Results of a Pilot Study." Liver Int 27.2 (2007): 268-73. http://www.ncbi.nlm.nih.gov/pubmed/17311623

Alkhouri N, ZeinNN."Protease Inhibitors: Silver Bullets for Chronic Hepatitis C Infection?" Cleve Clin J Med 79.3 (2012): 213-22. http://www.ncbi.nlm.nih.gov/pubmed/22383557

American College of Gastroenterology. "New Research on Improved Treatment Options and Screening Strategies for Hepatitis C." Available at: http://d2j7fjepcxuj0a.cloudfront.net/wp-content/uploads/2011/10/2011-ACG-Hepatitis-C-FINAL.pdf. October 31, 2011. Accessed March 9, 2012.

Angelico M. Epidemiology and outcome of hepatitis C relapse in transplant recipients. Transplant Proc. 2011 Jul-Aug;43(6):2457-8.

Arteh J, Narra S, Nair S. "Prevalence of vitamin D deficiency in chronic liver disease." Dig Dis Sci 55.9 (2010): 2624-8. http://www.ncbi.nlm.nih.gov/pubmed/19960254

Ashfaq UA, Masoud MS, Nawaz Z, et al. "Glycyrrhizin as Antiviral Agent against Hepatitis C Virus." J Transl Med 9 (2011): 112. http://www.biomedcentral.com/content/pdf/1479-5876-9-112.pdf

Aw TY, Wierzbicka G, and Jones DP. Oral glutathione increases tissue glutathione in vivo. ChemBiol Interact. 1991;80(1):89-97.

Azzam HS, Goertz C, Fritts M, et al. "Natural Products and Chronic Hepatitis C Virus." Liver Int 27.1 (2007): 17-25. http://www.ncbi.nlm.nih.gov/pubmed/17241377

Bachmetov L, Gal-Tanamy M, Shapira A, et al. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J Viral Hepat. 2012 Feb;19(2):e81-8.

Baek YH, Lee SW, Yoo HS, et al. "Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment." Gut Liver 1.1 (2007): 87-9. http://www.ncbi.nlm.nih.gov/pubmed/20485665

Beloqui O, Prieto J, Suárez M, et al. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res. 1993 Aug;13(4):279-82.

Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med Klin (Munich). 1999 Oct 15;94 Suppl 3:84-9.

Bonifaz V, Shan Y, Lambrecht RW, et al. "Effects of Silymarin on Hepatitis C Virus and Haem Oxygenase-1 Gene Expression in Human Hepatoma Cells." Liver Int 29.3 (2009): 366-73. http://www.ncbi.nlm.nih.gov/pubmed/18694403

Boots AW, Haenen GR, Bast A. "Health Effects of Quercetin: from Antioxidant to Nutraceutical." Eur J Pharmacol 585.2-3 (2008): 325-37. http://www.ncbi.nlm.nih.gov/pubmed/18417116

Boursier J, de Ledinghen V, Zarski JP, et al. "A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis C." Am J Gastroenterol 106.7 (2011): 1255-63. http://www.ncbi.nlm.nih.gov/pubmed/21468012

Boursier J, de Ledinghen V, Zarski JP, et al. "Comparison Of Eight Diagnostic Algorithms for Liver Fibrosis in Hepatitis C: New Algorithms Are More Precise And Entirely Noninvasive." Hepatology 55.1 (2012): 58-67.

Bravi F, Bosetti C, Tavani A, et al. "Coffee Drinking and Hepatocellular Carcinoma Risk: A Meta-Analysis." Hepatology 46.2 (2007): 430-5. http://www.ncbi.nlm.nih.gov/pubmed/17580359

Cacciatore I, Cornacchia C, Pinnen F, et al. “Prodrug Approach for Increasing Cellular Glutathione Levels.” Molecules 15.3 (2010): 1242-64.

Cales P, Boursier J, Oberti F, et al. FibroMeters: a family of blood tests for liver fibrosis. GastroenterolClin Biol. 2008 Sep;32(6 Suppl 1):40-51.

Cales P. Presentation; Angers University, France. Non-invasive evaluation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C). 3/21/2011. Available at: http://crm.therapyedge.com/wp-content/uploads/2011/08/fm_easl.pdf Accessed 5/31/2012.

Cavalheiro, Nde P. "Sexual Transmission of Hepatitis C." Rev Inst Med Trop Sao Paulo 49.5 (2007): 271-7. http://www.ncbi.nlm.nih.gov/pubmed/18026632

Chakravarty D, Lee WC, Chen YC, Jan YY, Lee P. Liver Transplantation. New Delhi, India: Jaypee Brothers Medical Publishers; 2010. http://bit.ly/Ag4Un5

Cheifetz AS, Brown A, Curry M, Moss AC. Oxford American Handbook of Gastroenterology and Hepatology. New York: Oxford University Press; 2011. http://bit.ly/y8zpDB

Chen D, Shien J, Tiley L, et al. "Curcumin Inhibits Influenza Virus Infection and Haemagglutination Activity." Food Chem 119.4 (2010): 1346-1351. http://www.sciencedirect.com/science/article/pii/S0308814609010553

Chen SL, Morgan TR. "The Natural History of Hepatitis C Virus (HCV) Infection." Int J Med Sci 3.2 (2006): 47-52. http://www.medsci.org/v03p0047.htm

Chien CF, Wu YT, Tsai TH. “Biological Analysis of Herbal Medicines Used for the Treatment of Liver Diseases.” Biomed Chromatogr 25.1-2 (2011):21-38.

Ciancio A, Andreone P, Kaiser S, et al. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? J Viral Hepat. 2012 Jan;19 Suppl 1:52-9. doi: 10.1111/j.1365-2893.2011.01524.x.

Ciancio A, Rizzetto M. "Thymalfasin in the Treatment of Hepatitis B and C." Ann N Y AcadSci 1194 (2010): 141-6. http://www.ncbi.nlm.nih.gov/pubmed/20536462

Ciesek S, von Hahn T, Colpitts CC, et al. "The Green Tea Polyphenol, Epigallocatechin-3-Gallate, Inhibits Hepatitis C Virus Entry." Hepatology 54.6 (2011): 1947-55.

Cyong JC, Ki SM, Iijima K, Kobayashi T, et al. "Clinical and pharmacological studies on liver diseases treated with Kampo herbal medicine." Am J Chin Med 28.3-4 (2000): 351-60. http://www.ncbi.nlm.nih.gov/pubmed/11154048

Darvesh AS, Aggarwal BB, Bishayee A, et al. Curcumin and liver cancer: a review. Curr Pharm Biotechnol. 2012 Jan;13(1):218-28.

De Domenico I, Ward DM, Kaplan J. "Hepcidin Regulation: Ironing Out the Details." J Clin Invest 117.7 (2007): 1755-8.

del Campo JA, López RA, Romero-Gómez M. "Insulin Resistance and Response to Antiviral Therapy in Chronic Hepatitis C: Mechanisms and Management." Dig Dis 28.1 (2010): 285-93. http://www.ncbi.nlm.nih.gov/pubmed/20460925

Desai TK, Jamil LH, Balasubramaniam M, et al. "Phlebotomy Improves Therapeutic Response to Interferon in Patients with Chronic Hepatitis C: A Meta-Analysis of Six Prospective Randomized Controlled Trials." Dig Dis Sci 53.3 (2008): 815-22. http://www.ncbi.nlm.nih.gov/pubmed/17846887

Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. "Iron Reduction As An Adjuvant To Interferon Therapy In Patients With Chronic Hepatitis C Who Have Previously Not Responded To Interferon: A Multicenter, Prospective, Randomized, Controlled Trial." Hepatology 32.1 (2000): 135-8. http://www.ncbi.nlm.nih.gov/pubmed/10869301

Dooley JS, Lok AS, Burroughs AK, Heathcote EJ, eds. Sherlock's Diseases of the Liver and Biliary System. 12th ed. Hoboken, NJ: Wiley-Blackwell; 2011.

Echosens. FibroScan® 502 Touch. Available at: http://www.echosens.com/Products/fibroscanr-502-touch.html Accessed 5/31/2012.

El-Attar GM, Saleh ZA, El-Shibiny SS. "The Use of Whey Protein Concentrate in Management of Chronic Hepatitis C: A Pilot Study." Aust. J. Basic Appl. Sci. 3.2 (2009): 1060-1069. http://insipub.net/ajbas/2009/1060-1069.pdf

El-Lakkany NM, Hammam OA, El-Maadawy WH, et al. "Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis." Parasit Vectors. 11.5 (2012): 9. http://www.ncbi.nlm.nih.gov/pubmed/22236605

Eurich D, Bahra M, Berg T, et al. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. ExpClin Transplant. 2011 Feb;9(1):1-6.

Favilli F, Marraccini P, Iantomasi T, et al. Effect of orally administered glutathione on glutathione levels in some organs of rats: role of specific transporters. Br J Nutr. 1997 Aug;78(2):293-300.

Feld JJ, Modi AA, El-Diwany R, et al. "S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders." Gastroenterology 140.3 (2011): 830-9. http://www.ncbi.nlm.nih.gov/pubmed/20854821

Ferenci P, Scherzer TM, Kerschner H, et al. "Silibinin Is a Potent Antiviral Agent in Patients with Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy." Gastroenterology 135.5 (2008): 1561-7. http://www.ncbi.nlm.nih.gov/pubmed/18771667

Feret B. "Boceprevir: A New Oral Protease Inhibitor for the Treatment of Chronic Hepatitis C." Formulary 46 (2011): 352-366.

Fierer DS, Uriel AJ, Carriero DC, et al. "Liver Fibrosis during an Outbreak of Acute Hepatitis C Virus Infection in HIV-Infected Men: A Prospective Cohort Study." J Infect Dis 198.5 (2008): 683-6. http://jid.oxfordjournals.org/content/198/5/683.long#F2

Filipowicz M, Bernsmeier C, Terracciano L, et al. S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. PLoS One. 2010 Nov 8;5(11):e15492.

Fort GG and Mikolich DJ. Ferri: Ferri's Clinical Advisor 2012, 1st ed. Available at: http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-0-323-05611-3..00017-3--sc0095&isbn=978-0-323-05611-3&uniqId=337149870-3#4-u1.0-B978-0-323-05611-3..00017-3--sc0095 Accessed 5/30/2012.

Freedman ND, Curto TM, Lindsay KL, et al. "Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin Therapy in Patients with Chronic Hepatitis C." Gastroenterology 140.7 (2011): 1961-9. http://www.gastrojournal.org/article/S0016-5085(11)00273-3/fulltext

Freedman ND, Everhart JE, Lindsay KL, et al. "Coffee Intake Is Associated with Lower Rates of Liver Disease Progression in Chronic Hepatitis C." Hepatology 50.5 (2009): 1360-9. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783828/?tool=pubmed

Fujinaga H, Tsutsumi T, Yotsuyanagi H, et al. "Hepatocarcinogenesis in Hepatitis C: HCV Shrewdly Exacerbates Oxidative Stress by Modulating Both Production and Scavenging of Reactive Oxygen Species." Oncology 81 Suppl 1 (2011): 11-7. http://www.ncbi.nlm.nih.gov/pubmed/22212930

Fujita N, Sugimoto R, Ma N, et al. "Comparison of Hepatic Oxidative DNA Damage in Patients with Chronic Hepatitis B and C." J Viral Hepat 15.7 (2008): 498-507. http://www.ncbi.nlm.nih.gov/pubmed/18331251

Fujita N, Sugimoto R, Takeo M, et al. "Hepcidin Expression in the Liver: Relatively Low Level in Patients with Chronic Hepatitis C." Mol Med 13.1-2 (2007): 97-104.

Ghany MG, Nelson DR, Strader DB, et al. "An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases." Hepatology 54.4 (2011): 1433-44. http://www.ncbi.nlm.nih.gov/pubmed/21898493

Girelli D, Pasino M, Goodnough JB, et al. "Reduced Serum Hepcidin Levels in Patients with Chronic Hepatitis C." J Hepatol 51.5 (2009): 845-52. http://www.ncbi.nlm.nih.gov/pubmed/19729219

Gomez EV, Perez YM, Sanchez HV, et al. "Antioxidant and Immunomodulatory Effects of Viusid in Patients with Chronic Hepatitis C." World J Gastroenterol 16.21 (2010): 2638-47.

Gonzalez O, Fontanes V, Raychaudhuri S, et al. "The Heat Shock Protein Inhibitor Quercetin Attenuates Hepatitis C Virus Production." Hepatology 50.6 (2009): 1756-64. http://www.ncbi.nlm.nih.gov/pubmed/19839005

Gordon FD, Kwo P, Vargas HE. Treatment of hepatitis C in liver transplant recipients. Liver Transpl. 2009 Feb;15(2):126-35.

Grant PR, Black A, Garcia N, et al. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study. J Med Virol. 2000 Aug;61(4):439-42.

Gundermann KJ, Kuenker A, Kuntz E, et al. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011;63(3):643-59.

Gunduz H, Karabay O, Tamer A, et al. N-acetyl cysteine therapy in acute viral hepatitis. World J Gastroenterol. 2003 Dec;9(12):2698-700.

Guyton KZ, Kensler TW. "Prevention of Liver Cancer." CurrOncol Rep. 4.6 (2002): 464-70. http://www.ncbi.nlm.nih.gov/pubmed/12354357

Hagen TM, Wierzbicka GT, Sillau AH, et al. Bioavailability of dietary glutathione: effect on plasma concentration. Am J Physiol. 1990 Oct;259(4 Pt 1):G524-9.

Hallberg L, Brune M, Erlandsson M, et al. "Calcium: Effect of Different Amounts On Nonheme- And Heme-Iron Absorption in Humans." Am J ClinNutr 53.1 (1991): 112-9. http://www.ncbi.nlm.nih.gov/pubmed/1984335

Hanlon J. University of Alberta. "Vaccine Discovered for Hep C." Available at: http://www.news.ualberta.ca/article.aspx?id=B04932D68EF6488A8DE62A463FFA7487. February 15, 2012. Accessed March 7, 2012.

Hawke RL, Schrieber SJ, Soule TA, et al. "Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients with Chronic Hepatitis C." J ClinPharmacol 50.4 (2010): 434-49. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086763/?tool=pubmed

Hepatitis C Technical Advisory Group. United States Department of Veterans Affairs. Hepatitis C and Hepatocellular Carcinoma. Updated 6/21/2005. Available at: http://www.hepatitis.va.gov/provider/reviews/HCC.asp Accessed 5/30/2012.

Hidaka I, Hino K, Korenaga M, et al. "Stronger Neo-Minophagen C, A Glycyrrhizin-Containing Preparation, Protects Liver against Carbon Tetrachloride-Induced Oxidative Stress in Transgenic Mice Expressing the Hepatitis C Virus Polyprotein." Liver Int 27.6 (2007): 845-53.

Himoto T, Hosomi N, Nakai S, et al. "Efficacy of Zinc Administration in Patients with Hepatitis C Virus-Related Chronic Liver Disease." Scand J Gastroenterol 42.9 (2007): 1078-87. http://www.ncbi.nlm.nih.gov/pubmed/17710674

Himoto T, Yoneyama H, Kurokohchi K, et al. "Selenium Deficiency Is Associated with Insulin Resistance in Patients with Hepatitis C Virus-Related Chronic Liver Disease." Nutr Res 31.11 (2011): 829-35. http://www.ncbi.nlm.nih.gov/pubmed/22118753

Hino K, Murakami Y, Nagai A, et al. "Alpha-Tocopherol [Corrected] and Ascorbic Acid Attenuates the Ribavirin [Corrected] Induced Decrease of Eicosapentaenoic Acid in Erythrocyte Membrane in Chronic Hepatitis C Patients." J Gastroenterol Hepatol 21.8 (2006): 1269-75. http://www.ncbi.nlm.nih.gov/pubmed/16872308

Hino K, Murakami Y, Nagai A, et al. “Alpha-Tocopherol [Corrected] and Ascorbic Acid Attenuates the Ribavirin [Corrected] Induced Decrease of Eicosapentaenoic Acid in Erythrocyte Membraine in Chronic Hepatitis C Patients.” J Gastroenterol Hepatol. 21.8 (2006):1269-75.

Holmberg S. "The Growing Burden of Mortality Associated with Viral Hepatitis in the United States, 1999-2007." The Liver Meeting 2011: American Association for the Study of Liver Diseases (AASLD) 62nd Annual Meeting. Abstract 243. Presented November 8, 2011. http://liverlearning.aasld.org/aasld/2011/thelivermeeting/14872/the.growing.burden.of.mortality.associated.with.viral.hepatitis.in.the.united.html

Iantomasi T, Favilli F, Marraccini P, et al. thione transport system in human small intestine epithelial cells. BiochimBiophysActa. 1997 Dec 4;1330(2):274-83.

Ishii K, Takamura N, Shinohara M, et al. "Long-Term Follow-Up of Chronic Hepatitis C Patients Treated with Oral Lactoferrin for 12 Months." Hepatol Res 25.3 (2003): 226-233. http://www.ncbi.nlm.nih.gov/pubmed/12697243

Jacobson IM, McHutchison JG, Dusheiko G, et al. "Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection." N Engl J Med 364.25 (2011): 2405-16. http://www.ncbi.nlm.nih.gov/pubmed/21696307

Jones DP, Hagen TM, Weber R, et al. Oral administration of glutathione (GSH) increases plasma GSH concentrations in humans, FASEB J., 3 (1989) A1250.

Kaito M, Iwasa M, Fujita N, et al. "Effect of Lactoferrin in Patients with Chronic Hepatitis C: Combination Therapy with Interferon and Ribavirin." J GastroenterolHepatol 22.11 (2007): 1894-7. http://www.ncbi.nlm.nih.gov/pubmed/17914966

Kariya C, Leitner H, Min E, et al. A role for CFTR in the elevation of glutathione levels in the lung by oral glutathione administration. Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1590-7.

Kato J, Miyanishi K, Kobune M, et al. "Long-Term Phlebotomy with Low-Iron Diet Therapy Lowers Risk of Development of Hepatocellular Carcinoma from Chronic Hepatitis C." J Gastroenterol 42.10 (2007): 830-6. http://www.ncbi.nlm.nih.gov/pubmed/17940836

Kawaguchi Y, Mizuta T, Takahashi K, et al. "High-Dose Vitamins E and C Supplementation Prevents Ribavirin-Induced Hemolytic Anemia in Patients with Chronic Hepatitis C." Hepatol Res 37.5 (2007): 317-24. http://www.ncbi.nlm.nih.gov/pubmed/17441803

Khan MS, Dilawar S, Ali I, et al. "The Possible Role of Selenium Concentration in Hepatitis B and C Patients." Saudi J Gastroenterol 18.2 (2012): 106-10. http://www.ncbi.nlm.nih.gov/pubmed/22421715

Kim JJ, Culley CM, Mohammad RA. "Telaprevir: An Oral Protease Inhibitor for Hepatitis C Virus Infection." Am J Health Syst Pharm 69.1 (2012): 19-33. http://www.ncbi.nlm.nih.gov/pubmed/22180548

Kim K, Kim KH, Kim HY, et al. "Curcumin Inhibits Hepatitis C Virus Replication via Suppressing the Akt-SREBP-1 Pathway." FEBS Lett 584.4 (2010): 707-12. http://www.ncbi.nlm.nih.gov/pubmed/20026048

Klatsky AL, Morton C, Udaltsova N, et al. "Coffee, Cirrhosis, and Transaminase Enzymes." Arch Intern Med 166.11 (2006): 1190-5. http://www.ncbi.nlm.nih.gov/pubmed/16772246

Ko WS, Guo CH, Hsu GS, et al. "The Effect of Zinc Supplementation on the Treatment of Chronic Hepatitis C Patients with Interferon and Ribavirin." ClinBiochem 38.7 (2005b): 614-20. http://www.ncbi.nlm.nih.gov/pubmed/15904908

Korenaga M, Hidaka I, Nishina S, et al. "A Glycyrrhizin-Containing Preparation Reduces Hepatic Steatosis Induced by Hepatitis C Virus Protein and Iron in Mice." Liver Int 31.4 (2011): 552-60.

Kortsalioudaki C, Taylor RM, Cheeseman P, et al. “Safety and Efficacy of N-Acetylcysteine in Children with Non-Acetaminophen-Induced Acute Liver Failure." Liver Transpl 14.1 (2008): 25-30. http://www.ncbi.nlm.nih.gov/pubmed/18161828

Krishnan SM, Dixit NM. "Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy." PLoSComput Biol. 7.2 (2011): e1001072. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033369/

Kumada H. "Long-Term Treatment of Chronic Hepatitis C with Glycyrrhizin [Stronger Neo-Minophagen C (SNMC)] for Preventing Liver Cirrhosis and Hepatocellular Carcinoma." Oncology 62 Suppl 1 (2002): 94-100. http://www.ncbi.nlm.nih.gov/pubmed/11868794

Kume H, Okazaki K, and Sasaki H. Hepatoprotective effects of whey protein on D-galactosamine-induced hepatitis and liver fibrosis in rats. BiosciBiotechnolBiochem. 2006 May;70(5):1281-5.

Kuntzen T, Timm J, Berical A, et al. "Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naïve Patients." Hepatology 48.6 (2008): 1769-78. http://www.ncbi.nlm.nih.gov/pubmed/19026009

Kwo PY, Lawitz EJ, McCone J, et al. "Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination with Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients with Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial." Lancet 376.9742 (2010): 705-16.

Larsson SC, Wolk A. "Coffee Consumption and Risk of Liver Cancer: A Meta-Analysis." Gastroenterology 132.5 (2007): 1740-5. http://www.ncbi.nlm.nih.gov/pubmed/17484871

Li CJ, Zhang LJ, Dezube BJ, et al. "Three Inhibitors of Type 1 Human Immunodeficiency Virus Long Terminal Repeat-Directed Gene Expression and Virus Replication." PNAS 90.5 (1993): 1839-1842. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC45975/

Li XL, Zhou AG, Zhang L, et al. "Antioxidant Status and Immune Activity of Glycyrrhizin in Allergic Rhinitis Mice." Int J MolSci 12.2 (2011): 905-16. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083680/

Lieber CS. "Pathogenesis and Treatment of Alcoholic Liver Disease: Progress over the Last 50 Years." RoczAkad Med Bialymst 50 (2005):7-20. http://www.ncbi.nlm.nih.gov/pubmed/16363067

Lo Re V 3rd, Teal V, Localio AR., et al. "Relationship between Adherence to Hepatitis C Virus Therapy and Virologic Outcomes: A Cohort Study." Ann Intern Med 155.6 (2011): 353-60. http://www.ncbi.nlm.nih.gov/pubmed/21930852

Loguercio C, Festi D. "Silybin and the Liver: From Basic Research to Clinical Practice." World J Gastroenterol 17.18 (2011): 2288-301. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098397/?tool=pubmed

Ma Q, Kim EY, Lindsay EA, et al. “Bioactive dietary polyphenols inhibit heme iron absorption in a dose-dependent manner in human intestinal caco-2 cells.” J Food Sci. 2011 Jun;76(5):H143-50.

Malaguarnera M, Vacante M, Bertino G, et al. "The Supplementation of Acetyl-L-Carnitine Decreases Fatigue and Increases Quality of Life in Patients with Hepatitis C Treated with Pegylated Interferon-α 2b Plus Ribavirin." J Interferon Cytokine Res 31.9 (2011b): 653-9. http://www.ncbi.nlm.nih.gov/pubmed/21923249

Malaguarnera M, Vacante M, Giordano M, et al. "L-Carnitine Supplementation Improves Hematological Pattern in Patients Affected by HCV Treated with Peg Interferon-α 2b Plus Ribavirin." World J Gastroenterol 17.39 (2011a): 4414-20. http://www.ncbi.nlm.nih.gov/pubmed/22110268

Matsuoka S, Matsumura H, Nakamura H, et al. "Zinc Supplementation Improves the Outcome of Chronic Hepatitis C and Liver Cirrhosis." J ClinBiochemNutr 45.3 (2009): 292-303. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771250/?tool=pubmed

Mayer KE, Myers RP, Lee SS. "Silymarin Treatment of Viral Hepatitis: A Systematic Review." J Viral Hepat 12.6 (2005): 559-67. http://www.ncbi.nlm.nih.gov/pubmed/16255756

Mayo Clinic. Hepatitis C. Updated 5/24/2011. Available at: http://www.mayoclinic.com/health/hepatitis-c/DS00097 Accessed: 5/29/2012.

McDonald J, Burroughs A, Feagan B, eds. Evidence-Based Gastroenterology &Hepatology. Hoboken, NJ: Wiley-Blackwell; 2010. http://bit.ly/z3ue7W

Medici V, Virata MC, Peerson JM, et al. "S-Adenosyl-L-Methionine Treatment for Alcoholic Liver Disease: A Double-Blinded, Randomized, Placebo-Controlled Trial." Alcohol ClinExp Res 35.11 (2011): 1960-5. http://www.ncbi.nlm.nih.gov/pubmed/22044287

Melhem A, Stern M, Shibolet O, et al. "Treatment of Chronic Hepatitis C Virus Infection via Antioxidants: Results of a Phase I Clinical Trial." J ClinGastroenterol 39.8 (2005): 737-42. http://www.ncbi.nlm.nih.gov/pubmed/16082287

Miura K, Taura K, Kodama Y, et al. "Hepatitis C Virus-Induced Oxidative Stress Suppresses Hepcidin Expression through Increased Histone Deacetylase Activity." Hepatology 48.5 (2008): 1420-9. http://www.ncbi.nlm.nih.gov/pubmed/18671304

Modi AA, Feld JJ, Park Y, et al. "Increased Caffeine Consumption Is Associated with Reduced Hepatic Fibrosis." Hepatology 51.1 (2010): 201-9. http://www.ncbi.nlm.nih.gov/pubmed/20034049

Morisco F, Vitaglione P, Carbone A, et al. "Tomato-Based Functional Food as Interferon Adjuvant in HCV Eradication Therapy." J ClinGastroenterol 38.6 Suppl (2004): S118-20. http://www.ncbi.nlm.nih.gov/pubmed/15220675

Morishima C, Shuhart MC, Wang CC, et al. "Silymarin Inhibits in Vitro T-Cell Proliferation and Cytokine Production in Hepatitis C Virus Infection." Gastroenterology 138.2 (2010): 671-81, 681.e1-2. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2819600/?tool=pubmed

Moriya K, Miyoshi H, Shinzawa S, et al. "Hepatitis C Virus Core Protein Compromises Iron-Induced Activation of Antioxidants in Mice and Hepg2 Cells." J Med Virol 82.5 (2010): 776-92. http://www.ncbi.nlm.nih.gov/pubmed/20336713

Munir S, Saleem S, Idrees M, et al. Hepatitis C treatment: current and future perspectives. Virol J. 2010 Nov 1;7:296.

Murakami Y, Koyabu T, Kawashima A, et al. "Zinc Supplementation Prevents the Increase of Transaminase in Chronic Hepatitis C Patients during Combination Therapy with Pegylated Interferon Alpha-2b and Ribavirin." J NutrSciVitaminol (Tokyo) 53.3 (2007): 213-8. http://www.ncbi.nlm.nih.gov/pubmed/17874825

Nahas R, Sheikh O. "Complementary and Alternative Medicine for the Treatment of Major Depressive Disorder." Can Fam Physician 57.6 (2011): 659-63. http://www.ncbi.nlm.nih.gov/pubmed/21673208

Nakashima K, Takeuchi K, Chihara K, et al. "Inhibition of Hepatitis C Virus Replication through Adenosine Monophosphate-Activated Protein Kinase-Dependent and -Independent Pathways." MicrobiolImmunol. 55.11 (2011): 774-82. http://www.ncbi.nlm.nih.gov/pubmed/21895746

Narang TK, Ahrens W, and Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010 Nov;16(11):1228-35.

Neumann UP, Biermer M, Eurich D, et al. "Successful Prevention of Hepatitis C Virus (HCV) Liver Graft Reinfection by Silibinin Mono-Therapy." J Hepatol 52.6 (2010): 951-2. http://www.ncbi.nlm.nih.gov/pubmed/20413176

Nguyen-Khac E, Thevenot T, Piquet MA, et al. "Glucocorticoids Plus N-Acetylcysteine in Severe Alcoholic Hepatitis." N Engl J Med 365.19 (2011): 1781-9. http://www.med.upenn.edu/gastro/documents/NACinAlcHep.pdf

Nielsen ML, Pareek M, Andersen I. "[Liquorice-Induced Hypertension and Hypokalaemia.]" UgeskrLaeger 174.15 (2012): 1024-1025. http://www.ncbi.nlm.nih.gov/pubmed/22487411

NIH (National Institutes of Health - National Institute of Allergy and Infectious Diseases). "Hepatitis C." Available at: http://www.niaid.nih.gov/topics/hepatitis/hepatitisc/Pages/Default.aspx. Last updated October 1, 2009. Accessed April 26, 2012.

NIH-NDDIC. National Digestive Diseases Information Clearinghouse; National Institutes of Health. Updated 5/10/2012. Available at: http://digestive.niddk.nih.gov/ddiseases/pubs/hepc_ez/#6 Accessed: 5/29/2012.

Nimer A, Mouch A. "Vitamin D Improves Viral Response in Hepatitis C Genotype 2-3 Naïve Patients." World J Gastroenterol 18.8 (2012): 800-5. http://www.wjgnet.com/1007-9327/pdf/v18/i8/800.pdf

Nishina S, Hino K, Korenaga M, et al. "Hepatitis C Virus-Induced Reactive Oxygen Species Raise Hepatic Iron Level in Mice by Reducing Hepcidin Transcription." Gastroenterology 134.1 (2008):226-38. http://www.ncbi.nlm.nih.gov/pubmed/18166355

Nkontchou G, Cosson E, Aout M, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J ClinEndocrinolMetab. 2011 Aug;96(8):2601-8.

Okiyama W, Tanaka N, Nakajima T, et al. "Polyenephosphatidylcholine Prevents Alcoholic Liver Disease in PPARalpha-Null Mice through Attenuation of Increases in Oxidative Stress." JHepatol 50.6 (2009): 1236-46. http://www.ncbi.nlm.nih.gov/pubmed/19398233

Park KG, Min AK, Koh EH, et al. "Alpha-Lipoic Acid Decreases Hepatic Lipogenesis through Adenosine Monophosphate-Activated Protein Kinase (AMPK)-Dependent and AMPK-Independent Pathways." Hepatology 48.5 (2008):1477-86. http://www.ncbi.nlm.nih.gov/pubmed/18972440

Petta S, Cammà C, Scazzone C, et al. "Low Vitamin D Serum Level Is Related to Severe Fibrosis and Low Responsiveness to Interferon-Based Therapy in Genotype 1 Chronic Hepatitis C." Hepatology 51.4 (2010): 1158-67. http://onlinelibrary.wiley.com/doi/10.1002/hep.23489/full

Polyak SJ, Morishima C, Shuhart MC, et al. "Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-Kappab Signaling, and HCV Infection by Standardized Silymarin." Gastroenterology 132.5 (2007): 1925-36. http://www.ncbi.nlm.nih.gov/pubmed/17484885

Poo JL, Sánchez Avila F, Kershenobich D, et al. "Efficacy of Triple Therapy with Thymalfasin, Peginterferon alpha-2a, and Ribavirin for the Treatment of Hispanic Chronic HCV Nonresponders." Ann Hepatol 7.4 (2008): 369-75. http://www.medigraphic.com/pdfs/hepato/ah-2008/ah084j.pdf

Poordad F, McCone J Jr, Bacon BR, et al. "Boceprevir for Untreated Chronic HCV Genotype 1 Infection." N Engl J Med 364.13 (2011): 1195-206. http://www.ncbi.nlm.nih.gov/pubmed/21449783

Poynard T, Ngo Y, Perazzo H, et al. Prognostic value of liver fibrosis biomarkers: a meta-analysis. GastroenterolHepatol (N Y). 2011 Jul;7(7):445-54.

Poynard T. Fibrosure (Fibrotest–ActiTest) – Towards a Universal Biomarker of Liver Fibrosis. Available at: http://www.touchbriefings.com/pdf/1043/LabCorp_tech.pdf Accessed. 5/31/2012.

Price L, Kowdley KV. "The Role of Iron in the Pathophysiology and Treatment of Chronic Hepatitis C." Can J Gastroenterol 23.12 (2009): 822-8. http://www.ncbi.nlm.nih.gov/pubmed/20011735

Rahman I, Biswas SK, Kirkham PA. "Regulation of Inflammation and Redox Signaling by Dietary Polyphenols." BiochemPharmacol. 72.11 (2006): 1439-52. http://www.ncbi.nlm.nih.gov/pubmed/16920072

Reddy KR, Shiffman ML, Morgan TR, et al. "Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment." ClinGastroenterolHepatol 5.1 (2007): 124-9. http://www.ncbi.nlm.nih.gov/pubmed/17196435

Rohr-Udilova N, Sieghart W, Eferl R, et al. "Antagonistic Effects of Selenium and Lipid Peroxides on Growth Control in Early Hepatocellular Carcinoma." Hepatology. 2012 Apr;55(4):1112-21.

Romero-Gómez M, Diago M, Andrade RJ, et al. "Treatment Of Insulin Resistance With Metformin In Naïve Genotype 1 Chronic Hepatitis C Patients Receiving Peginterferon Alfa-2a Plus Ribavirin." Hepatology 50.6 (2009): 1702-8. http://www.ncbi.nlm.nih.gov/pubmed/19845037

Rosen HR. Clinical Practice. Chronic Hepatitis C Infection. N Engl J Med 2011; 364:2429-2438 June 23, 2011

Rubin A, Aguilera V, and Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol. 2011 Dec;35(12):805-12. Epub 2011 Oct 1.

Ruhl CE, Everhart JE. "Coffee And Caffeine Consumption Reduce the Risk of Elevated Serum Alanine Aminotransferase Activity in the United States." Gastroenterology 128.1 (2005a): 24-32. http://www.ncbi.nlm.nih.gov/pubmed/15633120

Ruhl CE, Everhart JE. "Coffee and Tea Consumption Are Associated with a Lower Incidence of Chronic Liver Disease in the United States." Gastroenterology 129.6 (2005b): 1928-36.

Russmann S, Grattagliano I, Portincasa P, et al. "Ribavirin-Induced Anemia: Mechanisms, Risk Factors and Related Targets for Future Research." Curr Med Chem 13.27 (2006): 3351-7. http://www.ncbi.nlm.nih.gov/pubmed/17168855

Rutter K, Scherzer TM, Beinhardt S, et al. Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy. AntivirTher. 2011;16(8):1327-33.

Saewong T, Ounjaijean S, Mundee Y, et al. “Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice.” Med Chem. 2010 Mar;6(2):57-64.

Sainz B Jr, Barretto N, Martin DN, et al. "Identification of the Niemann-Pick C1-Like 1 Cholesterol Absorption Receptor as a New Hepatitis C Virus Entry Factor." Nat Med 18.2 (2012): 281-5. http://www.ncbi.nlm.nih.gov/pubmed/22231557

Sarrazin C, Zeuzem S. "Resistance to Direct Antiviral Agents in Patients with Hepatitis C Virus Infection." Gastroenterology 138.2 (2010): 447-62. http://www.ncbi.nlm.nih.gov/pubmed/20006612

Sartori M, Andorno S, Rossini A, et al. "A Case-Control Histological Study on the Effects of Phlebotomy in Patients with Chronic Hepatitis C." Eur J GastroenterolHepatol 23.12 (2011): 1178-84. http://www.ncbi.nlm.nih.gov/pubmed/22002003

Schmidt AJ, Rockstroh JK, Vogel M, et al. "Trouble with Bleeding: Risk Factors for Acute Hepatitis C among HIV-Positive Gay Men from Germany--A Case-Control Study." PLoS One 6.3 (2011): e17781. http://www.ncbi.nlm.nih.gov/pubmed/21408083

Schröfelbauer B, Raffetseder J, Hauner M, et al. "Glycyrrhizin, the Main Active Compound in Liquorice, Attenuates Pro-Inflammatory Responses by Interfering with Membrane-Dependent Receptor Signalling." Biochem J 421.3 (2009): 473-82. http://www.biochemj.org/bj/421/0473/bj4210473.htm

Seeff LB, Curto TM, Szabo G, et al. "Herbal Product Use by Persons Enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial." Hepatology 47.2 (2008): 605-12. http://www.ncbi.nlm.nih.gov/pubmed/18157835

Shawki A, Mackenzie B. "Interaction of Calcium with the Human Divalent Metal-Ion Transporter-1." BiochemBiophys Res Commun 393.3 (2010): 471-5. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838957/

Shay KP, Moreau RF, Smith EJ, et al. “Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.” BiochimBiophysActa 1790.10 (2009): 1149-60. http://www.ncbi.nlm.nih.gov/pubmed/19664690

Sherman KE, Flamm SL, Afdhal NH, et al. "Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection." N Engl J Med 365.11 (2011): 1014-24. http://www.ncbi.nlm.nih.gov/pubmed/21916639

Sherman KE. "Thymosin Alpha 1 for Treatment of Hepatitis C Virus: Promise and Proof." Ann N Y AcadSci 1194 (2010): 136-40.

Shiffman ML, ed. Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future. New York: Springer Science+Business Media, LLC; 2012.

Si X, Wang Y, Wong J, et al. "Dysregulation of the Ubiquitin-Proteasome System by Curcumin Suppresses Coxsackievirus B3 Replication." J Virol 81.7 (2007): 3142-50. http://www.ncbi.nlm.nih.gov/pubmed/17229707

Singal AK, Jampana SC, Weinman SA. "Antioxidants as Therapeutic Agents for Liver Disease." Liver Int 31.10 (2011): 1432-48. http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2011.02604.x/full

Sumida Y, Kanemasa K, Fukumoto K, et al. "Effects of Dietary Iron Reduction versus Phlebotomy in Patients with Chronic Hepatitis C: Results from a Randomized, Controlled Trial on 40 Japanese Patients." Intern Med 46.10 (2007): 637-42. http://www.ncbi.nlm.nih.gov/pubmed/17527035

Susser S, Welsch C, Wang Y, et al. "Characterization of Resistance to the Protease Inhibitor Boceprevir in Hepatitis C Virus-Infected Patients." Hepatology 50.6 (2009): 1709-18. http://www.ncbi.nlm.nih.gov/pubmed/19787809

Suzuki H, Takagi H, Sohara N, et al. "Triple Therapy of Interferon and Ribavirin with Zinc Supplementation for Patients with Chronic Hepatitis C: A Randomized Controlled Clinical Trial." World J Gastroenterol 12.8 (2006): 1265-9. http://www.ncbi.nlm.nih.gov/pubmed/16534882

Takagi H, Nagamine T, Abe T, et al. "Zinc Supplementation Enhances the Response to Interferon Therapy in Patients with Chronic Hepatitis C." J Viral Hepat 8.5 (2001): 367-71. http://www.ncbi.nlm.nih.gov/pubmed/11555194

Tapryal N, Mukhopadhyay C, Mishra MK, et al. "Glutathione Synthesis Inhibitor ButathioneSulfoximine Regulates Ceruloplasmin by Dual but Opposite Mechanism: Implication in Hepatic Iron Overload." Free RadicBiol Med 48.11 (2010): 1492-500.

Thevenot T, Di Martino V, Lunel-Fabiani F, et al. "[Complementary Treatments of Chronic Viral Hepatitis C]." GastroenterolClinBiol 30.2 (2006): 197-214.

Trappoliere M, Caligiuri A, Schmid M, et al. "Silybin, A Component of Sylimarin, Exerts Anti-Inflammatory and Anti-Fibrogenic Effects on Human Hepatic Stellate Cells." J Hepatol 50.6 (2009): 1102-11. http://www.ncbi.nlm.nih.gov/pubmed/19398228

Tsochatzis E, Papatheodoridis GV, Koliaraki V, et al. "Serum Hepcidin Levels Are Related to the Severity of Liver Histological Lesions in Chronic Hepatitis C." J Viral Hepat 17.11 (2010): 800-6.

U.S. Centers for Disease Control and Prevention (CDC). " Hepatitis C in the African American Community " Available at: http://www.cdc.gov/hepatitis/Populations/AAC-HepC.htm. Last updated March 1, 2012b. Accessed March 9, 2012.

U.S. Centers for Disease Control and Prevention (CDC). "Hepatitis C FAQs for the Public." Available at: http://www.cdc.gov/hepatitis/C/cFAQ.htm. Last updated April 26, 2012a. Accessed March 9, 2012.

U.S. Centers for Disease Control and Prevention (CDC). "Hepatitis C FAQs for Health Professionals." Available at: http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Last updated August 4, 2011. Accessed March 9, 2012.

U.S. Centers for Disease Control and Prevention (CDC). “CDC Announces First Ever National Hepatitis Testing Day and Proposes that All Baby Boomers Be Tested Once for Hepatitis C.”May 18, 2012c. Available at: http://www.cdc.gov/nchhstp/Newsroom/HepTestingRecsPressRelease2012.html Accessed 5/30/2012.

Vandelli C, Renzo F, Romanò L, et al. "Lack of Evidence of Sexual Transmission of Hepatitis C among Monogamous Couples: Results of a 10-Year Prospective Follow-Up Study." Am J Gastroenterol 99.5 (2004): 855-9. http://www.ncbi.nlm.nih.gov/pubmed/15128350

Vergniol J, Foucher J, Terrebonne E, et al. "Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients with Chronic Hepatitis C." Gastroenterology 140.7 (2011): 1970-9, 1979.e1-3. http://www.ncbi.nlm.nih.gov/pubmed/21376047

Verma S, Thuluvath PJ. "Complementary and Alternative Medicine in Hepatology: Review of the Evidence of Efficacy." ClinGastroenterolHepatol 5.4 (2007): 408-16. http://www.ncbi.nlm.nih.gov/pubmed/17222587

Vilar Gomez E, Gra Oramas B, Soler E, et al. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Liver Int. 27.2 (2007): 247-59.

Wagoner J, Negash A, Kane OJ, et al. "Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle." Hepatology 51.6 (2010): 1912-21. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909978/?tool=pubmed

Wang GF, Shi LP, Ren YD, et al. Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral Res. 2009 Aug;83(2):186-90.

Wang R, Kong J, Wang D, et al. "A Survey of Chinese Herbal Ingredients with Liver Protection Activities." Chin Med10.2 (2007): 5. http://www.ncbi.nlm.nih.gov/pubmed/17490493

Wilkins T, Malcolm JK, Raina D, et al. “Hepatitis C: Diagnosis and Treatment.” Am Fam Physician. 2010 Jun 1;81(11):1351-7. http://www.aafp.org/afp/2010/0601/p1351.html

Williams IT, Bell BP, Kuhnert W, Alter MJ. "Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006." Arch Intern Med 171.3 (2011): 242-8.

World Health Organization, Global Alert and Response. "Hepatitis C." Available at: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index1.html. Accessed March 9, 2012.

Yu JW, Sun LJ, Zhao YH. "The Effect of Metformin on the Efficacy of Antiviral Therapy in Patients with Genotype 1 Chronic Hepatitis C and Insulin Resistance." Int J Infect Dis 2012. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/22486858

Yuasa K, Naganuma A, Sato K, et al. "Zinc Is a Negative Regulator of Hepatitis C Virus RNA Replication." Liver Int 26.9 (2006): 1111-8. http://onlinelibrary.wiley.com/doi/10.1111/j.1478-3231.2006.01352.x/abstract

Zeuzem S, Andreone P, Pol S, et al. "Telaprevir for Retreatment of HCV Infection." N Engl J Med 364.25 (2011): 2417-28. http://www.ncbi.nlm.nih.gov/pubmed/21696308

Zeuzem S, et al. "SVR4 and SVR12 with an Interferon-Free Regimen of BI 201335 and BI 207127 +/- Ribavirin, in Treatment-Naive Patients with Chronic Genotype-1 HCV Infection." Abstract#101 presented at the International Liver CongressTM (ILC), 18 -22 April 2012. Summary available at: http://www.natap.org/2012/EASL/EASL_19.htm

Zhao QY, Wang HY, Zhang WX, et al. "[Protective Effect of Polyenylphosphatidyl Choline on Liver in Rat with Sepsis]." Zhongguo Wei Zhong Bing JiJiu Yi Xue 23.7 (2011): 401-4.